Zemaira Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to increased awareness of alpha-1 antitrypsin deficiency, development of plasma fractionation technologies, expansion of specialty respiratory clinics, improved diagnostic screening programs, early adoption of augmentation therapy.

The growth in the forecast period can be attributed to increasing investments in rare disease treatments, growing demand for long-term respiratory management, expansion of specialty pharmacy distribution, rising focus on personalized respiratory care, advancements in plasma protein therapeutics. Major trends in the forecast period include expansion of augmentation therapy adoption, increasing focus on rare respiratory disorders, growing demand for plasma-derived therapies, enhanced monitoring of long-term respiratory outcomes, rising emphasis on early diagnosis.

The rising prevalence of lung diseases is expected to drive the growth of the Zemaira market. Lung diseases, including asthma, pneumonia, chronic obstructive pulmonary disease (COPD), and lung cancer, impair normal lung function. Their increasing prevalence is fueled by factors such as tobacco use, air pollution, occupational hazards, and higher rates of respiratory infections. Zemaira, an intravenous infusion of human alpha-1 antitrypsin (AAT), restores deficient AAT levels in patients, helping prevent further lung damage, improve lung function, and reduce the risk of respiratory complications. For example, in November 2024, the Australian Institute of Health and Welfare reported that 2.8 million people (11%) were living with asthma in 2022, accounting for 2.5% of the total disease burden and 35% of the respiratory disease burden in 2023. There were 467 deaths (1.8 per 100,000 population) in 2022, representing 0.2% of all deaths. Therefore, the increasing prevalence of lung diseases is propelling the Zemaira market.

The growing number of clinical trials is expected to further boost the Zemaira market. Clinical trials are research studies conducted in humans to evaluate the safety, efficacy, and effectiveness of new treatments, drugs, or interventions. The rising prevalence of chronic and complex diseases has increased the demand for clinical trials to develop effective therapies. Clinical trials for Zemaira help generate essential evidence regarding safety and efficacy, supporting regulatory approvals and guiding optimal use. For instance, in December 2024, the Association of the British Pharmaceutical Industry (ABPI) reported that the number of pharmaceutical industry trials launched in the UK rose from 411 in 2022 to 426 in 2023, marking the second consecutive year of growth. Therefore, the expanding number of clinical trials is driving the Zemaira market.

A key trend in the Zemaira market is the introduction of advancements, such as larger vial sizes, to improve convenience and reduce treatment frequency. Larger vials allow healthcare professionals to prepare fewer vials per dose, simplifying treatment and enhancing patient adherence, particularly for those who face the burden of frequent infusions. For example, in January 2024, CSL Behring, a US-based biotechnology company, introduced 4- and 5-gram vials of Zemaira (Alpha1-Proteinase Inhibitor [Human]), building on the previously available 1-gram vials. This innovation simplifies preparation, reduces waste, and supports sustainability goals, while continuing to play a vital role in managing Alpha-1 Antitrypsin Deficiency by maintaining adequate protein levels in patients.

Major companies operating in the zemaira market are CSL Behring LLC.

North America was the largest region in the zemaira market in 2025. The regions covered in the zemaira market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the zemaira market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the zemaira market by increasing costs of imported plasma collection supplies, fractionation equipment, sterile filling systems, and cold-chain logistics required for biologic infusion therapies. Europe and North America are most affected due to reliance on international plasma supply chains and specialized manufacturing inputs. These tariffs can raise therapy costs and constrain supply availability. However, they are also encouraging domestic plasma collection expansion, localized manufacturing investments, and strengthened regional supply security for rare disease biologics.

The zemaira market research report is one of a series of new reports that provides zemaira market statistics, including zemaira industry global market size, regional shares, competitors with a zemaira market share, detailed zemaira market segments, market trends and opportunities, and any further data you may need to thrive in the zemaira industry. This zemaira market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Zemaira is an intravenous alpha1-proteinase inhibitor used as chronic augmentation therapy for adults with alpha-1 antitrypsin deficiency and emphysema. It works by increasing functional A1-PI levels in the blood, helping protect lung tissue, slow disease progression, and improve overall respiratory function and quality of life.

The main indications for Zemaira are alpha-1 antitrypsin deficiency, pulmonary emphysema, and chronic obstructive pulmonary disease (COPD). Alpha-1 antitrypsin deficiency is an inherited disorder that reduces the level of alpha-1 antitrypsin, a protein essential for protecting the lungs and liver from damage. Zemaira is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies, and is used by adult and geriatric patients.

The zemaira market consists of sales of lyophilized powder for injection and sterile solution. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.